Drugs / AKN-028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01573247 | Dec 2011 → Mar 2016 | acute myeloid leukemia | Akinion Pharmaceuticals AB | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKN-028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01573247 ↗ |
| Action | Inhibit | “It is a potent inhibitor of the FMS-like kinase 3 (FLT3)” PMID 24200998 ↗ Nov 2013 |
| Modality | Small molecule | — CHEMBL4790100 ↗ |
| Target | FLT3 | “It is a potent inhibitor of the FMS-like kinase 3 (FLT3)” PMID 24200998 ↗ Nov 2013 |